Form 4: Moderna CFO James Mock Awarded 188,761 Restricted Stock Units

Moderna's Chief Financial Officer, James Mock, was granted 188,761 restricted stock units that vest over time.

Summary

• James Mock, the Chief Financial Officer of Moderna, Inc., was granted 188,761 restricted stock units on December 5, 2024.
• These restricted stock units will vest over a period of time, with 25% vesting on December 5, 2025.
• The remaining 75% of the units will vest in twelve equal quarterly installments after the initial vesting date.
• The restricted stock units are convertible to common stock on vesting.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.

Positives

• The grant of restricted stock units aligns the CFO's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and contribution from the CFO.

Industry Context

The granting of restricted stock units is a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock-based compensation is a standard practice for executive compensation in the biotech industry.
• Companies like BioNTech and Novavax also use stock options and restricted stock units as part of their compensation packages.
• The vesting schedule of 25% after one year and the remainder over three years is a typical vesting schedule for these types of grants.

Stakeholder Impact

• Shareholders may view this as a positive sign of aligning management's interests with the company's long-term success.
• Employees may see this as a standard practice for executive compensation.

Key Dates

Keywords

restricted stock units, stock options, executive compensation, insider trading, Moderna, MRNA, James Mock, CFO